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Summary
Objectives: Previous studies from Lebanon have shown Gram-negative organisms to be the
predominant agents in febrile neutropenic patients. The objective of this study was to evaluate
the most current epidemiological trends among patients with neutropenic fever.
Methods: This prospective observational cohort study, the largest to date in the country, was
conducted at the American University of Beirut Medical Center between January 2001 and
December 2003, with the objective of describing the characteristics of patients with neutropenic
fever and to assess temporal trends.
Results: We included 177 episodes of neutropenic fever. The most common underlying malignancy
was lymphoma (42.4%). Gastrointestinal and abdominal infections were predominant (31.6%) and
23.7% of cases represented fever of unknown origin. Gram-negative organisms were responsible for
78.8% (26/33) of bloodstream infections compared to 33.3% (11/33) with Gram-positive organisms.
The in-hospital mortality rate in this study (12.1%) was considerably lower than in previous years.
Conclusions: Gram-negative organisms are persistently predominant in our center. In a developing
country like Lebanon with limited resources, lower mortality rates commensurate with worldwide
reports were successfully achieved in this high-risk patient population. Protocols and guidelines
should be adapted to the characteristics of individual institutions to ensure delivery of appropriate
care to febrile neutropenic patients.
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Infectious processes continue to pose a problem of consider-
able magnitude that impacts the quality of life and survival of
cancer patients presenting with neutropenic fever.1 Over the
past decade, advances in the field have been counterba-
lanced by a rising number of immunosuppressed patients with
a multitude of new risk factors for infection and an ongoing
emergence of antimicrobial resistance.2
In recent years, a shift in the epidemiology of infections in
febrile neutropenic patients in several parts of the world has
been observed towards predominance of Gram-positive
infections.3 This trend has not been corroborated in prior
studies from Lebanon where Gram-negative organisms still
occupied the biggest share of infecting agents, and where
mortality rates were significant.4—6 In this observational
cohort study, we describe the characteristics of patients
presenting with febrile neutropenic episodes during the first
three years of the 21st century, and compare the results to
two studies published previously from the same institution to
assess temporal trends over the past decade.
Materials and methods
Study location and patients
The study was conducted between January 2001 and Decem-
ber 2003 at the American University of Beirut Medical Center
(AUBMC), a 400-bed teaching hospital in Lebanon. Eligible
patients were individuals at least 13 years of age with
neutropenic fever following chemotherapy. Patients were
included more than once if they developed a second episode
of neutropenic fever during the study period. The definitions
of fever and neutropenia were based on the latest publishedTable 1 Trends in bloodstream infections in neutropenic fever in
Organism 1995—98 (N = 104)
Gram-negative organisms 18 (17.3)
Escherichia coli 9 (8.7)
Pseudomonas aeruginosa 5 (4.8)
Klebsiella spp 2 (1.9)
Enterobacter spp 0
Acinetobacter spp 1 (1.0)
Salmonella enteritidis 1 (1.0)
Bacteroides spp 0
Gram-positive organisms 12 (11.5)
CoNS 6 (5.8)
MSSA 2 (1.9)
MRSA 2 (1.9)
Viridans streptococcus 1 (1.0)
Group D streptococcus 0
Enterococcus spp 1 (1.0)
Bacillus spp 0
Candida albicans 0
Polymicrobial 0
No growth 74 (71.2)
CoNS, coagulase-negative staphylococci; MSSA, methicillin-susceptible
aureus.guidelines of the Infectious Diseases Society of America
(IDSA) on neutropenic fever.7 A focal infection was consid-
ered present if the patient had symptoms, radiographic
evidence, or a positive culture suggestive of infection at a
particular site. Patients were followed daily throughout their
hospital stay and information was collected in a prospective
fashion.
Statistical analysis
Data were entered into a database using SPSS 11.0 for
Windows (SPSS Inc, Chicago, IL, USA). Bivariate analysis
was performed using the Chi-square test for categorical
variables and the independent samples t-test for continuous
variables. Variables that were significant on bivariate analy-
sis were entered into a multivariate logistic regression model
using Stata 7.0 (Stata Corporation, College Station, TX, USA).
Ethical considerations
The study was approved by the Institutional Review Board at
AUBMC. Since this was an observational study, informed
consent was waived.
Results
Patient characteristics
During the study period, we identified 177 episodes of neu-
tropenic fever in 116 patients. Patient age ranged from 15 to
86 years, with a mean of 47.8 years. The most common
underlying malignancy was lymphoma (42.4%), followed by
leukemia (34.5%), and solid tumors (16.4%). Prophylactic
antibiotics had been given in 32 cases (18.1%).Lebanon
1999 (N = 50) 2001—04 (N = 177)
9 (18.0) 26 (14.7)
4 (8.0) 17 (9.6)
3 (6.0) 4 (2.3)
0 3 (1.7)
1 (2.0) 2 (1.1)
0 0
0 0
1 (2.0) 0
5 (10.0) 11 (6.2)
1 (2.0) 8 (4.5)
0 0
3 (6.0) 0
1 (2.0) 1 (0.6)
0 1 (0.6)
0 0
0 1 (0.6)
1 (2.0) 2 (1.1)
0 5 (2.8)
35 (70.0) 144 (81.4)
Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus
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The mean duration of neutropenia in our patient population
was 7.2 days. The majority of patients (62.2%) had severe
neutropenia, as defined by an absolute neutrophil count less
than 100 cells/mm3. Neutropenic episodes were labeled as
clinically documented infections (46.9%), microbiologically
documented infections (29.4%), or fever of unknown origin
(23.7%). The most common source of infection was the abdo-
men and gastrointestinal tract (31.6%), followed by the
respiratory system (20.9%).
Bloodstream infections
Positive blood cultures were documented in 33 episodes of
neutropenic fever (18.6%) (Table 1). This represents a lower
rate compared to previous years (30% in 1999 and 28.8% in
1995—98). Gram-negative organisms were responsible for 26
of 33 documented bloodstream infections compared to 11 of
33 infections with Gram-positive organisms. The rate of
Gram-negative bloodstream infections exceeded that of
Gram-positive bloodstream infections (14.7% vs. 6.2%), simi-
lar to the trend seen in the earlier studies, although to a
different degree. Whereas in the period from 1995 to 1998
the ratio of Gram-positive to Gram-negative infections was
1.5:1, this ratio became 1.8:1 in 1999, and in the current
study it was 2.4:1. Among the Gram-negative organisms,
Escherichia coli has been consistently the most commonly
isolated organism, followed by Pseudomonas aeruginosa.
Similarly in the Gram-positive bacteremia group, coagu-
lase-negative staphylococci continue to represent themajor-
ity of isolates. On the other hand, there were five episodes of
polymicrobial bloodstream infections in the latest patient
sample, which is a new and unique feature compared to the
earlier cohorts.
Treatment
Cefepime was the antimicrobial agent most commonly used
as first-line therapy in the studied episodes of neutropenic
fever (50.3%), followed by ceftazidime (36.7%) and pipera-
cillin/tazobactam (10.2%). Glycopeptides were used as addi-
tional first-line empiric treatment in 37 cases (20.9%).
Antifungal agents were used in 101 cases (57.1%), fluconazole
being used the most.
Outcome
Fourteen episodes of neutropenic fever (7.9%) led to a fatal
outcome, giving an in-hospital mortality rate of 12.1%. On
multivariate analysis, the only two variables associated with
increased in-hospital mortality were treatment modification
for clinical deterioration (OR = 21.26; 95% CI 4.14—109.25)
and duration of neutropenia (OR = 1.14; 95% CI 1.03—1.26).
Discussion
Until recently, the epidemiology of neutropenic fever in
Lebanon has been poorly described. Between 1995 and
1998, a prospective analysis of 104 episodes of neutropenic
fever was reported,5 and in 1999, a follow-up study was donedescribing 50 consecutive episodes.6 The current study was
carried out with the intention of testing the persistence of
the previously observed findings and to describe in more
detail the characteristics and outcome of patients with
neutropenic fever.
The etiology of bacteremia in febrile neutropenic patients
has witnessed momentous changes in the past few decades.
Whereas in the 1950s the major culprit was Staphylococcus
aureus, Gram-negative organisms, particularly P. aeruginosa,
had the upper hand in the two decades that followed. How-
ever, Gram-positive organisms had re-emerged as principal
players throughout the 1990s, spearheaded by coagulase-
negative staphylococci.8,9 Yet infections in the setting of
neutropenic fever are proving to be quite dynamic, as a
new trend is now starting to come into view, where Gram-
negative organisms seem to be resurfacing.10—12 Several
factors have been implicated in this ever-changing epide-
miology, namely the increased placement of indwelling
catheters, the administration of antimicrobial prophylaxis,
the nature of chemotherapeutic regimens currently in use, as
well as several environmental conditions that are still poorly
elucidated.3,7,9,13,14
In Lebanon, the pattern of infecting organisms in febrile
neutropenic patients has been rather static in direction but
not in magnitude.4—6 Data from this country extending over
the past decade have consistently found a higher prevalence
of Gram-negative infections. Not only did we show that
Gram-negative organisms caused 26 of 33 bloodstream infec-
tions in the current study, we also noted that the gap is
widening between Gram-positive and Gram-negative infec-
tions over time.
This trend does not seem to be shared by other countries
in the region, where all studies have confirmed the predo-
minance of Gram-negative infections.15—18 However, one
report from Pakistan has recently shown a slight preponder-
ance of infections with Gram-negative organisms (53%) com-
pared to Gram-positive organisms.19
A possible explanation of the observed high incidence of
Gram-negative infections in Lebanon is the relatively low
proportion of patients with indwelling catheters, although
increased prevalence of Gram-positive infections has also
been reported from other centers where long-term catheters
are not commonly used.3 Another probable contributing
factor is the low proportion of patients receiving antimicro-
bial prophylaxis compared to other studies. Prophylactic
regimens containing old generation quinolones lack effective
coverage against Gram-positive organisms and thus predis-
pose to breakthrough Gram-positive infections. However,
such regimens also promote the emergence of resistance
among Gram-negative pathogens. At a time when there is
a dire need to contain the rising antimicrobial resistance in
Gram-negative organisms in Lebanon,20 and in the absence of
a clear and consistent survival benefit, the decision to admin-
ister antimicrobial prophylaxis in afebrile neutropenic
patients should take into consideration the risks and benefits
of this practice.
We found an in-hospital mortality of 12.1% in the present
analysis compared to 20% in the two previous studies at
AUBMC.5,6 These results are still slightly higher but more
comparable to recent published data documenting mortality
rates ranging between 4 and 7%.19,21,22 The decrease in the
proportion of high-risk patients with leukemia in favor of
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the intermediate or low-risk group, could partially account
for the observed decrease in in-hospital mortality. None-
theless, in a developing country like Lebanon with limited
resources, a lower in-hospital mortality rate commensurate
with worldwide reports was achieved in this high-risk popula-
tion.
Conclusions
In this third study from AUBMC describing the characteristics
of patients with neutropenic fever, a continually increasing
prevalence of Gram-negative infections was observed. This
divergence from the worldwide reported data that denotes a
predominance of Gram-positive infections underscores the
importance of tailoring and revising international protocols
and guidelines to correspond to the unique composition of
our patient population. The considerable reduction in in-
hospital mortality that has been achieved over the years
attests to the success of this strategy.
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